Abstract 537P
Background
Pulmonary metastasectomy is a commonly performed operation, but with inconclusive evidence for effectiveness. The aim of this study is to investigate the patient outcome after pulmonary metastasectomy in sarcoma patients with pulmonary metastases.
Methods
We retrospectively reviewed patients undergoing pulmonary metastasectomy for metastatic soft tissue and bone sarcomas in a single center. Treatment-free interval (TFI) was defined as the duration from the last date of primary tumor treatment to pulmonary metastasectomy. Recurrence-free interval (RFI), defined as the time from pulmonary metastasectomy to identification of new pulmonary metastasis, was calculated to determine freedom from lung recurrence. Post-metastasectomy survival (PMS) was defined as the time from pulmonary metastasectomy to death. Kaplan-Meier plots and Log-rank test were used to identify prognostic factors.
Results
Data of 102 patients were include in the analysis. In the RFI analysis, 77.4% patients (79/102) developed new pulmonary metastasis after pulmonary metastasectomy, with a median duration of 8.9 months. The 2-year freedom from lung recurrence was 23.6% and 51.9% in patients with TFI less than 12 months and TFI more than 12 months, respectively (p = 0.040). In the PMS analysis, the extrathoracic recurrence (p = 0.004) and TFI, but not primary site tumor recurrence, were significant prognostic factors. The 2 and 5-year PMS rates were 68.5% and 38.1%, respectively, in patients in patients with TFI less than 12 months, compared to 80.3% and 67.6%, respectively, in patients with TFI more than 12 months (p = 0.028).
Conclusions
A significant proportion (77.4%) of patients developed lung recurrences after pulmonary metastasectomy for sarcoma. Patients with TFI more than 12 months were associated with higher rate of freedom from lung recurrence and better PMS after pulmonary metastasectomy for sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract